Home | Molecular Cancer Therapeutics

Read the June 2018 Issue!
Editor's Pick: ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Hatel Patel, et al.
Efficient Gene Silencing in Brain Tumors with Hydrophobically Modified siRNAs
Maire F. Osborn, et al.
Mechanistic Modeling of Antibody–Drug Conjugate Internalization at the Cellular Level Reveals Inefficient Processing Steps
Kenneth R. Durbin, et al.
Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients
J. Andrew Livingston, et al.

From the Current Issue

Review

Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes

Arthur Winer, Sylvia Adams and Paolo Mignatti

Mol Cancer Ther June 1 2018 17 (6) 1147-1155; DOI:10.1158/1535-7163.MCT-17-0646
Small Molecule Therapeutics

ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment

Hetal Patel, Manikandan Periyasamy, Georgina P. Sava, Alexander Bondke, Brian W. Slafer, Sebastian H. B. Kroll, Marion Barbazanges, Richard Starkey, Silvia Ottaviani, Alison Harrod, Eric O. Aboagye, Laki Buluwela, Matthew J. Fuchter, Anthony G. M. Barrett, R. Charles Coombes and Simak Ali

Mol Cancer Ther June 1 2018 17 (6) 1156-1166; DOI:10.1158/1535-7163.MCT-16-0847
Large Molecule Therapeutics

Efficient Gene Silencing in Brain Tumors with Hydrophobically Modified siRNAs

Maire F. Osborn, Andrew H. Coles, Diane Golebiowski, Dimas Echeverria, Michael P. Moazami, Jonathan K. Watts, Miguel Sena-Esteves and Anastasia Khvorova

Mol Cancer Ther June 1 2018 17 (6) 1251-1258; DOI:10.1158/1535-7163.MCT-17-1144
Cancer Biology and Translational Studies

The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer

Nicholas Forsythe, Alaa Refaat, Arman Javadi, Hajrah Khawaja, Jessica-Anne Weir, Heba Emam, Wendy L. Allen, Frank Burkamp, Vlad Popovici, Puthen V. Jithesh, Claudio Isella, Melissa J. Labonte, Ian G. Mills, Patrick G. Johnston and Sandra Van Schaeybroeck

Mol Cancer Ther June 1 2018 17 (6) 1280-1290; DOI:10.1158/1535-7163.MCT-17-0603
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

Analysis of HSP27 and the Autophagy Marker LC3B⁺ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients

J. Andrew Livingston, Wei-Lien Wang, Jen-Wei Tsai, Alexander J. Lazar, Cheuk Hong Leung, Heather Lin, Shailesh Advani, Najat Daw, Janice Santiago-O'Farrill, Mario Hollomon, Nancy B. Gordon and Eugenie S. Kleinerman

Mol Cancer Ther June 1 2018 17 (6) 1315-1323; DOI:10.1158/1535-7163.MCT-17-0901
Models and Technologies

Mechanistic Modeling of Antibody–Drug Conjugate Internalization at the Cellular Level Reveals Inefficient Processing Steps

Kenneth R. Durbin, Colin Phipps and Xiaoli Liao

Mol Cancer Ther June 1 2018 17 (6) 1341-1351; DOI:10.1158/1535-7163.MCT-17-0672

See the Table of Contents

Recent Reviews

Review

Engaging Anaphase Catastrophe Mechanisms to Eradicate Aneuploid Cancers

Masanori Kawakami, Lisa Maria Mustachio, Xi Liu and Ethan Dmitrovsky

Mol Cancer Ther April 1 2018 17 (4) 724-731; DOI:10.1158/1535-7163.MCT-17-1108
Review

Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer

Bayley A. Jones, Sooryanarayana Varambally and Rebecca C. Arend

Mol Cancer Ther March 1 2018 17 (3) 591-602; DOI:10.1158/1535-7163.MCT-17-0437
Review

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining “Actionability” of a Molecular Lesion and Patient Management Support

Young Kwang Chae, Alan P. Pan, Andrew A. Davis, Sandip P. Patel, Benedito A. Carneiro, Razelle Kurzrock and Francis J. Giles

Mol Cancer Ther December 1 2017 16 (12) 2645-2655; DOI:10.1158/1535-7163.MCT-17-0597

Main menu

User menu

Search

From the Current Issue

Recent Reviews

OnlineFirst Articles

Articles

Info for

About MCT